Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

Microbion

Pre-clinical

Pre-clinical

Therapeutic Approach

Anti-Infective

This program is studying pravibismane, a new inhaled antibiotic. In the lungs of people with CF, bacteria may form protective layers -- known as biofilms -- that make them more difficult to kill. Pravibismane may help break down biofilms and kill drug-resistant bacteria, such as multi-drug resistant Pseudomonas aeruginosa and nontuberculous mycobacteria.

Status

Laboratory studies to develop and test this compound are underway.

Sponsor

This program is sponsored by Microbion and partially funded by the Cystic Fibrosis Foundation.



Contact us about Microbion >